company background image
VCYT logo

Veracyte NasdaqGM:VCYT Stock Report

Last Price

US$39.18

Market Cap

US$3.0b

7D

-4.7%

1Y

66.3%

Updated

24 Feb, 2025

Data

Company Financials +

VCYT Stock Overview

Operates as a diagnostics company in the United States and internationally. More details

VCYT fundamental analysis
Snowflake Score
Valuation3/6
Future Growth4/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Veracyte, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Veracyte
Historical stock prices
Current Share PriceUS$39.18
52 Week HighUS$47.32
52 Week LowUS$18.61
Beta1.71
1 Month Change-10.57%
3 Month Change-8.54%
1 Year Change66.30%
3 Year Change40.94%
5 Year Change50.11%
Change since IPO195.70%

Recent News & Updates

Veracyte, Inc.'s (NASDAQ:VCYT) Intrinsic Value Is Potentially 50% Above Its Share Price

Jan 09
Veracyte, Inc.'s (NASDAQ:VCYT) Intrinsic Value Is Potentially 50% Above Its Share Price

Veracyte: Getting Frothy

Dec 11

Veracyte, Inc. (NASDAQ:VCYT) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Dec 01
Veracyte, Inc. (NASDAQ:VCYT) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Recent updates

Veracyte, Inc.'s (NASDAQ:VCYT) Intrinsic Value Is Potentially 50% Above Its Share Price

Jan 09
Veracyte, Inc.'s (NASDAQ:VCYT) Intrinsic Value Is Potentially 50% Above Its Share Price

Veracyte: Getting Frothy

Dec 11

Veracyte, Inc. (NASDAQ:VCYT) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Dec 01
Veracyte, Inc. (NASDAQ:VCYT) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking After Shares Rocket 42%

Aug 18
Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking After Shares Rocket 42%

Veracyte, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Aug 09
Veracyte, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Veracyte, Inc.'s (NASDAQ:VCYT) Intrinsic Value Is Potentially 76% Above Its Share Price

Jul 02
Veracyte, Inc.'s (NASDAQ:VCYT) Intrinsic Value Is Potentially 76% Above Its Share Price

Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking

Jun 06
Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking

Veracyte, Inc. (NASDAQ:VCYT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

May 09
Veracyte, Inc. (NASDAQ:VCYT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

Lacklustre Performance Is Driving Veracyte, Inc.'s (NASDAQ:VCYT) Low P/S

Apr 18
Lacklustre Performance Is Driving Veracyte, Inc.'s (NASDAQ:VCYT) Low P/S

A Look At The Intrinsic Value Of Veracyte, Inc. (NASDAQ:VCYT)

Mar 18
A Look At The Intrinsic Value Of Veracyte, Inc. (NASDAQ:VCYT)

Veracyte Percepta Genomic Sequencing Classifier demonstrates accuracy in lung cancer risk

Jul 13

Veracyte: Not A Healthy Diagnosis

May 12

Shareholder Returns

VCYTUS BiotechsUS Market
7D-4.7%2.2%-2.2%
1Y66.3%-1.9%18.3%

Return vs Industry: VCYT exceeded the US Biotechs industry which returned -1.9% over the past year.

Return vs Market: VCYT exceeded the US Market which returned 18.3% over the past year.

Price Volatility

Is VCYT's price volatile compared to industry and market?
VCYT volatility
VCYT Average Weekly Movement6.4%
Biotechs Industry Average Movement10.9%
Market Average Movement6.0%
10% most volatile stocks in US Market17.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: VCYT has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: VCYT's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2006815Marc Stapleywww.veracyte.com

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test.

Veracyte, Inc. Fundamentals Summary

How do Veracyte's earnings and revenue compare to its market cap?
VCYT fundamental statistics
Market capUS$3.04b
Earnings (TTM)-US$9.27m
Revenue (TTM)US$425.33m

7.1x

P/S Ratio

-327.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VCYT income statement (TTM)
RevenueUS$425.33m
Cost of RevenueUS$128.38m
Gross ProfitUS$296.96m
Other ExpensesUS$306.22m
Earnings-US$9.27m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 24, 2025

Earnings per share (EPS)-0.12
Gross Margin69.82%
Net Profit Margin-2.18%
Debt/Equity Ratio0%

How did VCYT perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/24 21:18
End of Day Share Price 2025/02/21 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Veracyte, Inc. is covered by 18 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sung Ji NamBTIG
Bryan BrokmeierCantor Fitzgerald & Co.
Matthew SykesGoldman Sachs